FDA Advisory Panel Votes to Support Grail's Multi-Cancer Blood Test Approval
What happened
On September 23, 2026, an FDA advisory panel reviewed Grail Inc.'s Galleri multi-cancer early detection blood test.
The Context
- Emerging technology: Multi-cancer early detection (MCED) tests like Galleri aim to identify tumors before symptoms appear, using cell-free DNA analysis.
- Target demographic: Grail developed Galleri for adults aged 50 and older, building on previous studies that highlighted challenges in reducing late-stage cancer diagnoses.
- Current status: The test has been available since 2021 under laboratory-developed test regulations, typically costing over $700, pending full FDA approval.
The Number
— This figure represents the positive predictive value of the test, indicating that it accurately predicts cancer in more than two-thirds of patients with a detected "cancer signal." This level of accuracy is crucial for professionals considering the implications for patient screening and healthcare strategies.
Takeaway
With the advisory panel's favorable vote, the FDA's final decision could lead to broader availability of the Galleri test, potentially transforming cancer screening practices.
UAE-based newspaper covering Gulf politics, society, and international developments.
"Gulf News is one of the UAE’s most prominent English-language publications."
— A47 Editor
FDA panel endorses first-of-a-kind cancer blood test from Grail
The FDA panel has endorsed Grail's innovative cancer blood test, marking a significant step in the high-stakes review process aimed at enhancing early cancer detection. This first-of-its-kind test is designed to identify multiple types of cancer thro...
A curated Gulf News feed featuring major stories across news, business, opinion, and lifestyle.
"Gulf News is a major UAE newspaper whose featured stories feed reflects a broad editorial mix shaped for a Gulf audience."
— A47 Editor
FDA panel endorses first-of-a-kind cancer blood test from Grail
The FDA panel has endorsed Grail's innovative cancer blood test, marking a significant step in the high-stakes review process aimed at enhancing early cancer detection. This first-of-its-kind test is designed to identify multiple types of cancer thro...
Science and technology stories including AI.
"Longstanding science magazine with thoughtful AI coverage."
— A47 Editor
Blood test for multiple cancers clears crucial hurdle on track to FDA approval
A blood test designed to detect multiple cancers has successfully cleared a significant hurdle in its path toward FDA approval, indicating potential for early cancer detection. Experts emphasize that further research is necessary before it can be wid...
Scientific research, technology, environment, and society.
"Scientific American is one of the oldest and most authoritative science magazines, known for deep dives into science, technology, and society."
— A47 Editor
Blood test for multiple cancers clears crucial hurdle on track to FDA approval
A blood test designed to detect multiple cancers has successfully cleared a significant hurdle in its path toward FDA approval, indicating potential for early cancer detection. Experts emphasize that further research is necessary before it can be wid...
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
Grail’s Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval
Grail's multi-cancer blood test, Galleri, has received a positive recommendation from an FDA advisory panel for premarket approval, marking a significant advancement in cancer diagnostics. The FDA is expected to make its final ruling in the coming mo...
Major U.S. developments and regional news.
"ABC News delivers broad national coverage with a mainstream editorial stance, focusing on accessibility and balanced reporting."
— A47 Editor
Grail's cancer blood test faces high-stakes FDA review
Grail's innovative blood test, designed to detect signs of multiple cancers in healthy individuals, is undergoing its first significant review by the U.S. Food and Drug Administration (FDA). This regulatory assessment marks a critical step in the pot...
Medical reporting with scientific depth and public service tone.
"NPR is a nonprofit media organization offering thoughtful, in-depth journalism and storytelling, often with a liberal or progressive slant."
— A47 Editor
FDA advisory panel recommends a first: multi-cancer blood test
An independent advisory panel has recommended the FDA approve Grail's Galleri blood test, which claims to detect up to 50 types of cancer. This marks a significant step in cancer diagnostics, as it could enable earlier detection of various cancers th...